DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia
Treatment

Interventions: Drug: Zanubrutinib

First Posted Date: 2022-01-28

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT05214391

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Phase 2

Recruiting

Conditions: Thrombocytopenia
Treatment
Antiphospholipid Syndrome

Interventions: Drug: zanubrutinib

First Posted Date: 2022-01-20

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 10

Registration Number: NCT05199909

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

Early Phase 1

Recruiting

Conditions: Hemophilia B

Interventions: Genetic: VGB-R04

First Posted Date: 2021-12-10

Last Posted Date: 2025-02-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 3

Registration Number: NCT05152732

Locations: 🇨🇳
Blood diseases hospital, Tianjin, Tianjin, China

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2

Recruiting

Conditions: Refractory Hodgkin Lymphoma
Relapse
Hodgkin Lymphoma, Adult

Interventions: Drug: PD-1 inhibitor

First Posted Date: 2021-11-30

Last Posted Date: 2021-12-17

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 47

Registration Number: NCT05137886

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Phase 4

Terminated

Conditions: Acute Leukemia

Interventions: Drug: Imatinib
Drug: Flumatinib

First Posted Date: 2021-10-08

Last Posted Date: 2025-05-01

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 39

Registration Number: NCT05071482

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia
Autoantibodies
Evan Syndrome
Connective Tissue Diseases

Interventions: Drug: Avatrombopag

First Posted Date: 2021-08-06

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 52

Registration Number: NCT04993885

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Phase 2

Not yet recruiting

Conditions: Richter Transformation

Interventions: Drug: R-EPOCH in Combination With Ibrutinib

First Posted Date: 2021-08-05

Last Posted Date: 2021-08-05

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT04992377

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
The First affiliated hospital of China medical university, Shenyang, Liaoning, China

and more 8 locations

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia (ITP)
Autoantibodies
Evan Syndrome
Connective Tissue Diseases

Interventions: Drug: Combined use of TPO-RAs with low-dose anti-CD20 antibody
Drug: The best available therapy

First Posted Date: 2021-06-07

Last Posted Date: 2024-07-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 94

Registration Number: NCT04915482

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years

Not Applicable

Recruiting

Conditions: Primary Immune Thrombocytopenic Purpura

Interventions: Drug: TPO-RA

First Posted Date: 2021-05-18

Last Posted Date: 2025-02-24

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 100

Registration Number: NCT04890041

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

Phase 2

Terminated

Conditions: Refractory Aplastic Anemia

Interventions: Drug: Decitabine

First Posted Date: 2021-04-22

Last Posted Date: 2022-08-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 3

Registration Number: NCT04854889

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy